BayesDesign: Bayesian Single-Arm Design with Survival Endpoints
The proposed event-driven approach for Bayesian two-stage single-arm phase II trial design is a novel clinical trial design and can be regarded as an extension of the Simon’s two-stage design with the time-to-event endpoint. This design is motivated by cancer clinical trials with immunotherapy and molecularly targeted therapy, in which time-to-event endpoint is often a desired endpoint.
||Chia-Wei Hsu [aut, cre],
Haitao Pan [aut],
Jianrong Wu [aut]
||Chia-Wei Hsu <Chia-Wei.Hsu at stjude.org>
Please use the canonical form
to link to this page.